Published in Nature on February 15, 2012
MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer (2013) 3.60
Assessing the ceRNA hypothesis with quantitative measurements of miRNA and target abundance. Mol Cell (2014) 2.83
MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer (2012) 2.78
TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell (2012) 2.60
CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res (2012) 2.57
Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis. Cell (2012) 2.50
GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nat Cell Biol (2013) 2.03
Endogenous tRNA-Derived Fragments Suppress Breast Cancer Progression via YBX1 Displacement. Cell (2015) 2.01
IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest (2014) 2.01
Adult-specific functions of animal microRNAs. Nat Rev Genet (2013) 1.89
Structural basis for microRNA targeting. Science (2014) 1.77
Extracellular metabolic energetics can promote cancer progression. Cell (2015) 1.74
Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol (2013) 1.73
Stress response of glioblastoma cells mediated by miR-17-5p targeting PTEN and the passenger strand miR-17-3p targeting MDM2. Oncotarget (2012) 1.65
Dephosphorylation of tyrosine 393 in argonaute 2 by protein tyrosine phosphatase 1B regulates gene silencing in oncogenic RAS-induced senescence. Mol Cell (2014) 1.58
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene (2013) 1.55
Differential expression of circulating microRNAs according to severity of colorectal neoplasia. Transl Res (2015) 1.50
Analysis of Deregulated microRNAs and Their Target Genes in Gastric Cancer. PLoS One (2015) 1.50
Adrenocortical carcinoma. Endocr Rev (2013) 1.46
An essential mesenchymal function for miR-143/145 in intestinal epithelial regeneration. Cell (2014) 1.44
Analysis of microRNA-target interactions across diverse cancer types. Nat Struct Mol Biol (2013) 1.41
MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin (2014) 1.40
MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells. Oncotarget (2014) 1.30
Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells. J Clin Invest (2013) 1.28
The miRNA plasma signature in response to acute aerobic exercise and endurance training. PLoS One (2014) 1.22
Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes. Br J Cancer (2013) 1.20
MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment. Oncogene (2015) 1.16
Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomas. Int J Biol Sci (2012) 1.14
microRNA-mediated regulation of the tumor microenvironment. Cell Cycle (2013) 1.14
miRNA biogenesis: biological impact in the development of cancer. Cancer Biol Ther (2014) 1.13
Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. J Transl Med (2013) 1.11
miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma. PLoS One (2013) 1.10
NCG 4.0: the network of cancer genes in the era of massive mutational screenings of cancer genomes. Database (Oxford) (2014) 1.10
Akt-p53-miR-365-cyclin D1/cdc25A axis contributes to gastric tumorigenesis induced by PTEN deficiency. Nat Commun (2013) 1.09
Changes in microRNA expression in the MG-63 osteosarcoma cell line compared with osteoblasts. Oncol Lett (2012) 1.08
Prognostic value of miR-221-3p, miR-342-3p and miR-491-5p expression in colon cancer. Am J Transl Res (2014) 1.07
Ablation of PRMT6 reveals a role as a negative transcriptional regulator of the p53 tumor suppressor. Nucleic Acids Res (2012) 1.07
Deep sequencing of RNA from three different extracellular vesicle (EV) subtypes released from the human LIM1863 colon cancer cell line uncovers distinct miRNA-enrichment signatures. PLoS One (2014) 1.07
MicroRNAs in hepatocellular carcinoma: carcinogenesis, progression, and therapeutic target. Biomed Res Int (2014) 1.07
MicroRNA-31 functions as a tumor suppressor by regulating cell cycle and epithelial-mesenchymal transition regulatory proteins in liver cancer. Oncotarget (2015) 1.05
p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance. Front Oncol (2012) 1.04
Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. Br J Cancer (2014) 1.03
Noncoding RNA in oncogenesis: a new era of identifying key players. Int J Mol Sci (2013) 1.03
miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR. Sci Signal (2013) 1.02
MicroRNA-212 suppresses tumor growth of human hepatocellular carcinoma by targeting FOXA1. Oncotarget (2015) 1.02
miR-26a enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis. Oncogene (2013) 1.02
MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biol Ther (2013) 1.01
Genetics and epigenetics of adrenocortical tumors. Mol Cell Endocrinol (2013) 1.01
Antitumor effect of miR-197 targeting in p53 wild-type lung cancer. Cell Death Differ (2014) 1.00
MiR-196a promotes pancreatic cancer progression by targeting nuclear factor kappa-B-inhibitor alpha. PLoS One (2014) 0.99
miR-203, a tumor suppressor frequently down-regulated by promoter hypermethylation in rhabdomyosarcoma. J Biol Chem (2013) 0.97
MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours. Br J Cancer (2013) 0.97
MicroRNA-7 sensitizes non-small cell lung cancer cells to paclitaxel. Oncol Lett (2014) 0.97
A death-promoting role for ISG54/IFIT2. J Interferon Cytokine Res (2013) 0.96
miR-101 suppresses vascular endothelial growth factor C that inhibits migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells. PLoS One (2015) 0.96
Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs. Clin Exp Metastasis (2014) 0.96
microRNAs and ceRNAs: RNA networks in pathogenesis of cancer. Chin J Cancer Res (2013) 0.96
The PTTG1-targeting miRNAs miR-329, miR-300, miR-381, and miR-655 inhibit pituitary tumor cell tumorigenesis and are involved in a p53/PTTG1 regulation feedback loop. Oncotarget (2015) 0.95
Re-thinking miRNA-mRNA interactions: intertwining issues confound target discovery. Bioessays (2015) 0.95
p19Arf represses platelet-derived growth factor receptor β by transcriptional and posttranscriptional mechanisms. Mol Cell Biol (2012) 0.95
MicroRNA-26a regulates insulin sensitivity and metabolism of glucose and lipids. J Clin Invest (2015) 0.95
Noncoding RNA as therapeutic targets for hepatocellular carcinoma. Semin Liver Dis (2015) 0.94
miR-127 regulates cell proliferation and senescence by targeting BCL6. PLoS One (2013) 0.94
Rewiring of an epithelial differentiation factor, miR-203, to inhibit human squamous cell carcinoma metastasis. Cell Rep (2014) 0.94
Logic reversibility and thermodynamic irreversibility demonstrated by DNAzyme-based Toffoli and Fredkin logic gates. Proc Natl Acad Sci U S A (2012) 0.94
In vivo, Argonaute-bound microRNAs exist predominantly in a reservoir of low molecular weight complexes not associated with mRNA. Proc Natl Acad Sci U S A (2015) 0.94
Tumor suppressor function of miR-483-3p on squamous cell carcinomas due to its pro-apoptotic properties. Cell Cycle (2013) 0.94
Genetics and epigenetics of arrhythmia and heart failure. Front Genet (2013) 0.94
Dysregulation of microRNA biogenesis in cancer: the impact of mutant p53 on Drosha complex activity. J Exp Clin Cancer Res (2016) 0.94
Noncoding RNAs as novel biomarkers in prostate cancer. Biomed Res Int (2014) 0.93
Activation of miR200 by c-Myb depends on ZEB1 expression and miR200 promoter methylation. Cell Cycle (2013) 0.93
MicroRNA-214 suppresses oncogenesis and exerts impact on prognosis by targeting PDRG1 in bladder cancer. PLoS One (2015) 0.93
Exosome-mediated transfer of miR-222 is sufficient to increase tumor malignancy in melanoma. J Transl Med (2016) 0.92
MicroRNA-18a inhibits hypoxia-inducible factor 1α activity and lung metastasis in basal breast cancers. Breast Cancer Res (2014) 0.92
Regulatory Roles for Long ncRNA and mRNA. Cancers (Basel) (2013) 0.92
IL-1 receptor regulates microRNA-135b expression in a negative feedback mechanism during cigarette smoke-induced inflammation. J Immunol (2013) 0.92
MicroRNA-155 promotes glioma cell proliferation via the regulation of MXI1. PLoS One (2013) 0.92
Muscle specific miRNAs are induced by testosterone and independently upregulated by age. Front Physiol (2014) 0.91
EGF Receptor Promotes Prostate Cancer Bone Metastasis by Downregulating miR-1 and Activating TWIST1. Cancer Res (2015) 0.91
microRNAs in liver disease: from diagnostics to therapeutics. Clin Biochem (2013) 0.91
Circulating microRNAs as diagnostic and prognostic tools for hepatocellular carcinoma. World J Gastroenterol (2015) 0.90
A meta-analysis of microRNA expression in liver cancer. PLoS One (2014) 0.90
Low expression of miR-196b enhances the expression of BCR-ABL1 and HOXA9 oncogenes in chronic myeloid leukemogenesis. PLoS One (2013) 0.90
Differential expression profiling and functional analysis of microRNAs through stage I-III papillary thyroid carcinoma. Int J Med Sci (2013) 0.90
PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia. Cancer Res (2015) 0.90
The impact of post-transcriptional regulation in the p53 network. Brief Funct Genomics (2012) 0.89
Targeting microRNAs as key modulators of tumor immune response. J Exp Clin Cancer Res (2016) 0.89
MicroRNAs in Vascular Biology. Int J Vasc Med (2012) 0.89
Down-regulation of the antisense mitochondrial non-coding RNAs (ncRNAs) is a unique vulnerability of cancer cells and a potential target for cancer therapy. J Biol Chem (2014) 0.88
Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance. Oncotarget (2014) 0.88
Regulation of miRNA biogenesis as an integrated component of growth factor signaling. Curr Opin Cell Biol (2013) 0.88
Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis. Oncogene (2015) 0.88
miR-661 downregulates both Mdm2 and Mdm4 to activate p53. Cell Death Differ (2013) 0.88
The mTOR pathway negatively controls ATM by up-regulating miRNAs. Proc Natl Acad Sci U S A (2013) 0.88
A multidimensional platform for the purification of non-coding RNA species. Nucleic Acids Res (2013) 0.88
Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring. Cancer Metastasis Rev (2015) 0.88
MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-α. Mol Cancer (2016) 0.87
NEK9-dependent proliferation of cancer cells lacking functional p53. Sci Rep (2014) 0.87
miR-17-5p targets the p300/CBP-associated factor and modulates androgen receptor transcriptional activity in cultured prostate cancer cells. BMC Cancer (2012) 0.87
Regulation of the microRNA 200b (miRNA-200b) by transcriptional regulators PEA3 and ELK-1 protein affects expression of Pin1 protein to control anoikis. J Biol Chem (2013) 0.87
Hallmarks of cancer: the next generation. Cell (2011) 140.01
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell (1993) 64.62
Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell (1993) 33.79
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 32.26
c-Myc-regulated microRNAs modulate E2F1 expression. Nature (2005) 31.81
RAS is regulated by the let-7 microRNA family. Cell (2005) 30.24
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med (2005) 26.02
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell (2006) 23.59
Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature (2007) 21.53
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res (2005) 18.58
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet (2007) 15.46
Endogenous human microRNAs that suppress breast cancer metastasis. Nature (2008) 14.37
A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature (2010) 13.82
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature (2009) 13.28
Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science (2007) 12.42
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell (2009) 11.10
Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev (2006) 11.04
Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet (2007) 10.78
Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A (2006) 10.65
Retracted A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell (2009) 10.51
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science (2009) 10.30
MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A (2007) 9.82
Intronic microRNA precursors that bypass Drosha processing. Nature (2007) 9.65
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell (2009) 8.64
Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell (2006) 8.46
Modulation of microRNA processing by p53. Nature (2009) 7.88
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (2008) 7.59
Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet (2006) 7.53
Epigenetic modifications and human disease. Nat Biotechnol (2010) 7.29
MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol (2008) 7.27
Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A (2008) 6.89
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol (2010) 6.67
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature (2010) 6.37
Pervasive roles of microRNAs in cardiovascular biology. Nature (2011) 6.08
Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov (2010) 6.07
Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med (2008) 5.97
An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet (2003) 5.82
The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med (2008) 5.74
OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature (2010) 5.73
A hexanucleotide element directs microRNA nuclear import. Science (2007) 5.71
A genetic screen for candidate tumor suppressors identifies REST. Cell (2005) 5.61
An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell (2008) 5.47
microRNAs join the p53 network--another piece in the tumour-suppression puzzle. Nat Rev Cancer (2007) 5.38
Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA (2007) 5.35
Most Caenorhabditis elegans microRNAs are individually not essential for development or viability. PLoS Genet (2007) 5.33
A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci U S A (2005) 5.29
Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev (2009) 5.21
miR-19 is a key oncogenic component of mir-17-92. Genes Dev (2009) 4.95
A MicroRNA targeting dicer for metastasis control. Cell (2010) 4.81
Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet (2011) 4.81
The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell (2010) 4.71
Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev (2009) 4.43
Small RNA sorting: matchmaking for Argonautes. Nat Rev Genet (2010) 4.27
Retracted A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet (2009) 3.88
p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol (2011) 3.85
Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med (2011) 3.82
Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell (2010) 3.81
A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell (2011) 3.69
In-depth characterization of the microRNA transcriptome in a leukemia progression model. Genome Res (2008) 3.55
Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell (2010) 3.52
TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature (2010) 3.37
Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi. Nat Biotechnol (2010) 3.33
Transcriptional control of gene expression by microRNAs. Cell (2010) 3.05
miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep (2009) 3.03
MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med (2010) 2.99
p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med (2011) 2.93
Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer. Proc Natl Acad Sci U S A (2010) 2.91
Functional identification of optimized RNAi triggers using a massively parallel sensor assay. Mol Cell (2011) 2.82
A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell (2010) 2.78
MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol Cell (2010) 2.59
Sequence variations of microRNAs in human cancer: alterations in predicted secondary structure do not affect processing. Cancer Res (2006) 2.59
P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci U S A (2010) 2.49
Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat Cell Biol (2010) 2.40
Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev (2010) 2.37
Transgenic microRNA inhibition with spatiotemporal specificity in intact organisms. Nat Methods (2009) 2.32
Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci U S A (2011) 2.21
Emerging paradigms of regulated microRNA processing. Genes Dev (2010) 2.06
Small-molecule inhibitors of microrna miR-21 function. Angew Chem Int Ed Engl (2008) 2.00
miR-605 joins p53 network to form a p53:miR-605:Mdm2 positive feedback loop in response to stress. EMBO J (2011) 1.98
Negative regulation of tumor suppressor p53 by microRNA miR-504. Mol Cell (2010) 1.92
Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell (2011) 1.86
Non-coding RNAs take centre stage in epithelial-to-mesenchymal transition. Trends Cell Biol (2008) 1.82
Reversible gene knockdown in mice using a tight, inducible shRNA expression system. Nucleic Acids Res (2007) 1.64
Myc: Maestro of MicroRNAs. Genes Cancer (2010) 1.58
Sponge transgenic mouse model reveals important roles for the microRNA-183 (miR-183)/96/182 cluster in postmitotic photoreceptors of the retina. J Biol Chem (2011) 1.38
A resource of vectors and ES cells for targeted deletion of microRNAs in mice. Nat Biotechnol (2011) 1.36
miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat Med (2010) 1.35
Mutated beta-catenin evades a microRNA-dependent regulatory loop. Proc Natl Acad Sci U S A (2011) 1.08
Combinatorial effects of microRNAs to suppress the Myc oncogenic pathway. Blood (2011) 1.02
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
A microRNA component of the p53 tumour suppressor network. Nature (2007) 19.25
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell (2003) 11.40
Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet (2005) 8.99
Senescence of activated stellate cells limits liver fibrosis. Cell (2008) 8.98
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature (2004) 8.76
Apoptosis: a link between cancer genetics and chemotherapy. Cell (2002) 7.86
A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell (2002) 6.76
Dissecting p53 tumor suppressor functions in vivo. Cancer Cell (2002) 6.24
The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol (2007) 6.16
Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell (2006) 5.88
An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet (2003) 5.82
Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J (2003) 5.61
An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell (2008) 5.47
microRNAs join the p53 network--another piece in the tumour-suppression puzzle. Nat Rev Cancer (2007) 5.38
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature (2005) 4.97
miR-19 is a key oncogenic component of mir-17-92. Genes Dev (2009) 4.95
A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell (2006) 4.74
Control of apoptosis by p53. Oncogene (2003) 4.46
Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature (2004) 4.41
miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A (2009) 4.15
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 4.09
Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature (2006) 3.90
Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell (2010) 3.81
A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell (2011) 3.69
Apoptosis and melanoma chemoresistance. Oncogene (2003) 3.58
Dissecting eIF4E action in tumorigenesis. Genes Dev (2007) 3.53
Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer (2009) 3.52
A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44
Suppression of tumorigenesis by the p53 target PUMA. Proc Natl Acad Sci U S A (2004) 3.42
Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi. Nat Biotechnol (2010) 3.33
Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol (2002) 3.08
Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity. Genes Dev (2011) 3.05
p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev (2005) 3.02
Stem cells: The promises and perils of p53. Nature (2009) 3.01
Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol (2002) 3.00
A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proc Natl Acad Sci U S A (2012) 2.85
Functional identification of optimized RNAi triggers using a massively parallel sensor assay. Mol Cell (2011) 2.82
Mouse models of human AML accurately predict chemotherapy response. Genes Dev (2009) 2.75
Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol (2002) 2.61
DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev (2008) 2.60
Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell (2011) 2.56
Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell (2009) 2.54
Tissue-specific and reversible RNA interference in transgenic mice. Nat Genet (2007) 2.54
Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A (2008) 2.53
mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci U S A (2008) 2.50
Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev (2012) 2.44
PML is a direct p53 target that modulates p53 effector functions. Mol Cell (2004) 2.40
Non-cell-autonomous tumor suppression by p53. Cell (2013) 2.40
Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest (2008) 2.40
Senescence comes of age. Nat Med (2005) 2.39
An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev (2011) 2.38
Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res (2005) 2.37
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell (2012) 2.29
HIF-1 antagonizes p53-mediated apoptosis through a secreted neuronal tyrosinase. Nature (2010) 2.23
Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet (2002) 2.23
The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest (2006) 2.18
TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol (2009) 2.15
Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev (2013) 2.12
Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol (2009) 2.10
Independence of repressive histone marks and chromatin compaction during senescent heterochromatic layer formation. Mol Cell (2012) 2.02
Induction of sarcomas by mutant IDH2. Genes Dev (2013) 2.02
Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci U S A (2012) 1.97
A tumour suppressor network relying on the polyamine-hypusine axis. Nature (2012) 1.85
Gene mutations and genomic rearrangements in the mouse as a result of transposon mobilization from chromosomal concatemers. PLoS Genet (2006) 1.84
Non-germline genetically engineered mouse models for translational cancer research. Nat Rev Cancer (2010) 1.80
A pipeline for the generation of shRNA transgenic mice. Nat Protoc (2012) 1.76
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci U S A (2006) 1.71
The p400 E1A-associated protein is a novel component of the p53 --> p21 senescence pathway. Genes Dev (2005) 1.70
A combinatorial strategy for treating KRAS-mutant lung cancer. Nature (2016) 1.69
Mutation discovery in mice by whole exome sequencing. Genome Biol (2011) 1.69
Genes and transposons are differentially methylated in plants, but not in mammals. Genome Res (2003) 1.66
p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev (2010) 1.66
Role of the chromobox protein CBX7 in lymphomagenesis. Proc Natl Acad Sci U S A (2007) 1.65
Towards patient-based cancer therapeutics. Nat Biotechnol (2010) 1.63
Generation and characterization of Smac/DIABLO-deficient mice. Mol Cell Biol (2002) 1.61
Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev (2008) 1.60
Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res (2006) 1.60
Akt phosphorylation of deleted in liver cancer 1 abrogates its suppression of liver cancer tumorigenesis and metastasis. Gastroenterology (2010) 1.52
The splicing-factor oncoprotein SF2/ASF activates mTORC1. Proc Natl Acad Sci U S A (2008) 1.42
p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J Exp Med (2013) 1.34
The atypical E2F family member E2F7 couples the p53 and RB pathways during cellular senescence. Genes Dev (2012) 1.33
Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology (2009) 1.32
MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. Cancer Res (2009) 1.30
H3K4 demethylation by Jarid1a and Jarid1b contributes to retinoblastoma-mediated gene silencing during cellular senescence. Proc Natl Acad Sci U S A (2012) 1.28
Reversible suppression of an essential gene in adult mice using transgenic RNA interference. Proc Natl Acad Sci U S A (2011) 1.23
Eating to exit: autophagy-enabled senescence revealed. Genes Dev (2009) 1.20
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. Proc Natl Acad Sci U S A (2013) 1.19
p400 is required for E1A to promote apoptosis. J Biol Chem (2005) 1.19
Tumor promotion by Mdm2 splice variants unable to bind p53. Cancer Res (2003) 1.17
Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. J Exp Med (2010) 1.15
Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis. Cell Rep (2012) 1.12
Characterization of cells and gene-targeted mice deficient for the p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1). Proc Natl Acad Sci U S A (2003) 1.11
The price of tumour suppression? Nature (2002) 1.10
The specific role of pRb in p16 (INK4A) -mediated arrest of normal and malignant human breast cells. Cell Cycle (2012) 1.10
A conserved element in Myc that negatively regulates its proapoptotic activity. EMBO Rep (2005) 1.09